CVS HEALTH Corp: Form 10-K for the period ended Dec 31, 2010
Filed with the SEC on Feb 18, 2011 and accepted by EDGAR at Feb 18, 2011, 16:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2010-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2010-10-01 to 2010-12-31 | $24.77bn | us-gaap:Revenues |
| Revenue | 12 months2010-01-01 to 2010-12-31 | $96.41bn | us-gaap:Revenues |
| Cost of revenue | 12 months2010-01-01 to 2010-12-31 | $76.16bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2010-10-01 to 2010-12-31 | $5.47bn | us-gaap:GrossProfit |
| Gross profit | 12 months2010-01-01 to 2010-12-31 | $20.26bn | us-gaap:GrossProfit |
| Operating income | 3 months2010-10-01 to 2010-12-31 | $1.77bn | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2010-01-01 to 2010-12-31 | $6.17bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2010-01-01 to 2010-12-31 | $539.0m | us-gaap:InterestExpense |
| Income tax | 12 months2010-01-01 to 2010-12-31 | $2.19bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2010-10-01 to 2010-12-31 | $1.03bn | us-gaap:NetIncomeLoss |
| Net income | 12 months2010-01-01 to 2010-12-31 | $3.43bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2010-10-01 to 2010-12-31 | $0.75 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2010-01-01 to 2010-12-31 | $2.49 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2010-10-01 to 2010-12-31 | $0.75 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2010-01-01 to 2010-12-31 | $2.51 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2010-01-01 to 2010-12-31 | 1,377,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2010-01-01 to 2010-12-31 | $4.78bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2010-01-01 to 2010-12-31 | $2.00bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2010-01-01 to 2010-12-31 | $479.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2010-01-01 to 2010-12-31 | $1.50bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2010-12-31 | $1.43bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2010-12-31 | $17.71bn | us-gaap:AssetsCurrent |
| Total assets | At period end2010-12-31 | $62.17bn | us-gaap:Assets |
| Current liabilities | At period end2010-12-31 | $11.07bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2010-12-31 | $8.65bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2010-12-31 | $1.10bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2010-12-31 | $300.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2010-12-31 | $37.70bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-11-040351. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.